Screener
Alnylam Pharmaceuticals ALNY Regeneron Technology Transfer Obligation — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Alnylam Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 8:11 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001178670-26-000062
| (In thousands) | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Research Services Obligation | $(802) | $12,957 | $5,831 | $26,767 |
| C5 License Obligation | — | — | — | 21,458 |
| Regeneron Technology Transfer Obligation | — | — | — | 2,431 |
| Other license programs | 5,822 | 19,585 | 45,525 | 32,925 |
| Total | $5,020 | $32,542 | $51,356 | $83,581 |
Cover / Front Matter
FAQ
- What is Alnylam Pharmaceuticals's regeneron technology transfer obligation — total revenues?
- Alnylam Pharmaceuticals (ALNY) reported regeneron technology transfer obligation — total revenues of $0 in Q2 2026.
- What does regeneron technology transfer obligation — total revenues mean?
- Represents the total revenue recognized during the reporting period specifically attributable to the technology transfer obligation under the Regeneron collaboration agreement. This metric captures the financial inflow realized as the company satisfies its performance obligations related to transferring intellectual property or technical expertise to the partner. It serves as a key indicator of the progress and monetization of specific collaborative research and development arrangements.
Ask your AI about Alnylam Pharmaceuticals's regeneron technology transfer obligation — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude